Keyphrases
Head-and-neck Cancer
76%
High-risk Human Papillomavirus (HR-HPV)
72%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
65%
Head-and-neck
57%
Overall Survival
43%
Transoral Robotic Surgery
39%
Nasopharyngeal Carcinoma
32%
Radiation Therapy
32%
Radiotherapy
30%
Cancer Patients
27%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
26%
Chemoradiotherapy
25%
National Cancer Database
22%
High Risk
21%
Intermediate Risk
21%
Adjuvant Radiotherapy
20%
Adjuvant Radiation Therapy
19%
Adjuvant Therapy
19%
HPV+
18%
Locally Advanced
16%
Extracapsular Extension
16%
Locoregional Control
16%
Endometrial Cancer
16%
5-fluorouracil (5-FU)
16%
Computed Tomography
15%
Squamous Cell Carcinoma of Head
15%
Clinical Outcomes
15%
Intensity-modulated Radiation Therapy
15%
Adjuvant Radiation
15%
External Beam Radiotherapy
15%
Progression-free Survival
14%
Squamous Cell Cancer
14%
Prognostic Significance
14%
Intraoperative Radiation Therapy
13%
Distant Control
13%
HPV-related Oropharyngeal Cancer
13%
Induction Chemotherapy
12%
Brachytherapy
11%
Intensity-modulated Radiotherapy
11%
Treatment Outcome
11%
Reduced Dose
11%
HDR Brachytherapy
10%
Treatment Planning
10%
Extranodal Extension
10%
Elderly Patients
9%
Local Control
9%
Neck Radiation
9%
Hydroxyurea
9%
Malignant Pleural Mesothelioma
9%
Re-irradiation
9%
Medicine and Dentistry
Radiation Therapy
100%
Oropharynx Carcinoma
79%
Neck
61%
Wart Virus
58%
Overall Survival
46%
Head and Neck Cancer
42%
Robot-Assisted Surgery
39%
Chemoradiotherapy
38%
Malignant Neoplasm
34%
Diseases
33%
Squamous Cell Carcinoma
25%
Recurrent Disease
25%
Head and Neck Squamous Cell Carcinoma
22%
Cancer
21%
Adjuvant Radiotherapy
21%
Brachytherapy
21%
Adjuvant Therapy
19%
Uterine Cancer
19%
Intensity Modulated Radiation Therapy
18%
Computer Assisted Tomography
17%
Treatment Planning
17%
Cervical Cancer
16%
Oropharynx Squamous Cell Carcinoma
15%
Squamous Cell
14%
Cancer Cell
14%
External Beam Radiotherapy
14%
Progression Free Survival
13%
Neoplasm
12%
Metastatic Carcinoma
11%
Systematic Review
10%
High-Dose-Rate Brachytherapy
9%
Pleura Mesothelioma
9%
Volumetric Modulated Arc Therapy
9%
Contouring
9%
Oral
9%
Quality of Life
9%
Lymph Node
9%
Adjuvant Chemoradiotherapy
9%
Pelvis
8%
Survival Rate
8%
Hazard Ratio
8%
Base
8%
Contralateral
7%
Induction Chemotherapy
7%
Proportional Hazards Model
6%
Patient Population
6%
Multivariate Analysis
6%
Oncology
6%
Clinical Trial
6%
Tongue
6%